Close Menu

As part of the ongoing quest to find effective delivery methods for RNAi drugs, a team of researchers at Duke University has combined aptamers with siRNAs to create a cell type-specific gene-silencing agent capable of inhibiting tumor growth and mediating tumor regression in an animal model of prostate cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Bloomberg reports that vaccine developers won't have to conduct large trials of updated vaccines or vaccine boosters aimed at new viral variants.

The SARS-CoV-2 variant uncovered in California may be more transmissible and partially evade vaccine-induced antibody response, the Los Angeles Times reports.

Francis deSouza, the CEO of Illumina, calls for a global SARS-CoV-2 genomics surveillance network, according to the Financial Times.

In PNAS this week: immunotherapy for hard-to-treat breast cancers, effects of oncogenic histone H3K36M mutations, and more.

Mar
09
Sponsored by
Fabric Genomics

The growth of next-generation sequencing (NGS) testing presents both opportunities and challenges for clinical, informatics, and laboratory teams. 

Mar
11
Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
24
Sponsored by
Mission Bio

This webinar, the first in a “Women in Single Cell” series sponsored by Mission Bio, will discuss the use of single-cell analysis to assess genome editing for use in pre-clinical disease modeling.